ACTELION PHARMACEUTICALS US, INC.

Actelion Pharmaceuticals US, Inc. specializes in the manufacturing and supply of complex pharmaceutical preparations, with deep expertise in specialty medications for pulmonary hypertension, including branded therapies such as Uptravi, Opsumit, and Tyvaso. The company demonstrates advanced capability in GMP-compliant production of oral and inhaled formulations, ensuring consistent quality and regulatory adherence for mission-critical drug products. Their technical proficiency extends to multi-dose packaging, controlled distribution logistics, and compliance with FDA and DEA requirements for high-risk therapeutics, positioning them as a reliable source for medications requiring stringent handling and traceability. The contractor maintains a strong, recurring relationship with the Department of Veterans Affairs and the Department of Justice, consistently delivering specialized pharmaceuticals to support inmate healthcare programs and veteran-specific treatment protocols. For the VA, they supply long-term maintenance medications for chronic conditions; for the DOJ, they provide targeted therapies for pulmonary arterial hypertension within correctional health systems, indicating a nuanced understanding of institutional formularies and dosing protocols in custodial care environments. Operating under NAICS 325412, Actelion focuses exclusively on pharmaceutical preparation manufacturing, with a vertical specialization in rare disease therapeutics and high-cost specialty drugs requiring precise compounding and stability control. Their market positioning is defined by niche expertise in pulmonology-focused biologics and small-molecule formulations, serving federal agencies that require reliable access to high-complexity, low-volume medications. As a 2L entity based in Titusville, New Jersey, Actelion operates as a mid-sized manufacturer without federal certifications such as 8(a), HUBZone, or WOSB. Their geographic footprint is centered on U.S. federal supply chain needs, with no indication of international or commercial market diversification, reinforcing their role as a dedicated government contractor in the specialty pharmaceutical space.